# Activin signaling inhibitors

Drug · id `cardio:activin-signaling-inhibitors` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Activin Signaling Inhibitor; Activin Signaling Inhibitors

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Activin signaling inhibitors are medicines that block signals carried by activin and related growth factors. The US label of Winrevair (sotatercept) calls it an activin signaling inhibitor that binds activin A and other growth factors of the same family, and says this improves the balance between signals that drive and signals that hold back the growth of blood vessel cells. A narrative review published in November 2026 calls targeting BMP/activin signaling a major advance in pulmonary arterial hypertension, and says a treatment framework recognizes it as a fourth treatment pathway alongside endothelin, nitric oxide and prostacyclin. Sotatercept is the only medicine in this group so far, and it has its own page. This is the class page.

## Technical summary

Class page. The name and aliases use the RxClass class names: the established pharmacologic class on US drug labels Activin Signaling Inhibitor (EPC, class N0000194100) and the mechanism-of-action class Activin Signaling Inhibitors (read 2026-11-19). RxClass lists sotatercept as the only member of the EPC class, so sotatercept is filed here on that evidence. MeSH has descriptors for activins and activin receptors, which are the target and not the medicine class, so no MeSH identifier is recorded. Sources: the Winrevair label (BLA761363, effective 2026-09-21), whose mechanism section describes the class action, and a 2026 narrative review (PMC13764490, Journal of Clinical Medicine, CC BY 4.0) that describes BMP/activin signaling as a treatment pathway in pulmonary arterial hypertension. The review attributes the four-pathway framework to the 7th World Symposium on Pulmonary Hypertension; that document was not read. No trial result, dose or instruction is recorded.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- The Winrevair label lists pulmonary arterial hypertension as the indication of its one member: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Has subtype: Sotatercept (`cardio:sotatercept`)

## Provenance

Content hash: a7cdcf47ac45192a1f23f1754b425e2bb8ccd478f304a0927a1ab30ee09828a8
Last substantive edit: 2026-11-19
Evidence last checked: 2026-11-19
